ACT Now, or Flop Later (Though Sooner Than You Might Expect)

Though clearly capable of achieving dramatic clinical performance, cancer cell therapies face considerable commercial challenges owing to the unprecedented cost and complexity of these modalities.  What the field needs, therefore, are not only companies capable of achieving clinical success but those that are at the same time looking ahead to and persuading investors and partners how their programs can achieve commercial success.  As the field (hopefully) continues to mature, we’ll have lessons not only of what not to do but perhaps a clearer path on how to simultaneously win in the clinic AND the marketplace.